BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34799039)

  • 1. Updated Approach to Patients with Multiple Café au Lait Macules.
    Albaghdadi M; Thibodeau ML; Lara-Corrales I
    Dermatol Clin; 2022 Jan; 40(1):9-23. PubMed ID: 34799039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting neurofibromatosis type 1 risk among children with isolated café-au-lait macules.
    Ben-Shachar S; Dubov T; Toledano-Alhadef H; Mashiah J; Sprecher E; Constantini S; Leshno M; Messiaen LM
    J Am Acad Dermatol; 2017 Jun; 76(6):1077-1083.e3. PubMed ID: 28318682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of a café-au-lait macules screening clinic: Experience from The Hospital for Sick Children in Toronto.
    Albaghdadi M; Berseneva M; Pennal A; Wan S; Matviychuk D; Shugar A; Kannu P; Lara-Corrales I
    Pediatr Dermatol; 2022 Mar; 39(2):205-210. PubMed ID: 35178768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature.
    Bernier A; Larbrisseau A; Perreault S
    Pediatr Neurol; 2016 Jul; 60():24-29.e1. PubMed ID: 27212418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Café au Lait Macules and Associated Genetic Syndromes.
    Anderson S
    J Pediatr Health Care; 2020; 34(1):71-81. PubMed ID: 31831114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Legius Syndrome and its Relationship with Neurofibromatosis Type 1.
    Denayer E; Legius E
    Acta Derm Venereol; 2020 Mar; 100(7):adv00093. PubMed ID: 32147744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of multiple café-au-lait macules for neurofibromatosis 1 in Chinese children.
    Yao R; Wang L; Yu Y; Wang J; Shen Y
    J Dermatol; 2016 May; 43(5):537-42. PubMed ID: 26458495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1.
    Nunley KS; Gao F; Albers AC; Bayliss SJ; Gutmann DH
    Arch Dermatol; 2009 Aug; 145(8):883-7. PubMed ID: 19687418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational spectrum by phenotype: panel-based NGS testing of patients with clinical suspicion of RASopathy and children with multiple café-au-lait macules.
    Castellanos E; Rosas I; Negro A; Gel B; Alibés A; Baena N; Pineda M; Pi G; Pintos G; Salvador H; Lázaro C; Blanco I; Vilageliu L; Brems H; Grinberg D; Legius E; Serra E
    Clin Genet; 2020 Feb; 97(2):264-275. PubMed ID: 31573083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
    Messiaen L; Yao S; Brems H; Callens T; Sathienkijkanchai A; Denayer E; Spencer E; Arn P; Babovic-Vuksanovic D; Bay C; Bobele G; Cohen BH; Escobar L; Eunpu D; Grebe T; Greenstein R; Hachen R; Irons M; Kronn D; Lemire E; Leppig K; Lim C; McDonald M; Narayanan V; Pearn A; Pedersen R; Powell B; Shapiro LR; Skidmore D; Tegay D; Thiese H; Zackai EH; Vijzelaar R; Taniguchi K; Ayada T; Okamoto F; Yoshimura A; Parret A; Korf B; Legius E
    JAMA; 2009 Nov; 302(19):2111-8. PubMed ID: 19920235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic variability among café-au-lait macules in neurofibromatosis type 1.
    Boyd KP; Gao L; Feng R; Beasley M; Messiaen L; Korf BR; Theos A
    J Am Acad Dermatol; 2010 Sep; 63(3):440-7. PubMed ID: 20605257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
    Brems H; Legius E
    Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choroidal abnormalities in café-au-lait syndromes: a new differential diagnostic tool?
    Cassiman C; Casteels I; Jacob J; Plasschaert E; Brems H; Dubron K; Keer KV; Legius E
    Clin Genet; 2017 Apr; 91(4):529-535. PubMed ID: 27716896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic analyses of mosaic neurofibromatosis type 1 with giant café-au-lait macule, plexiform neurofibroma and multiple melanocytic nevi.
    Hida T; Idogawa M; Okura M; Sugita S; Sugawara T; Sasaki Y; Tokino T; Yamashita T; Uhara H
    J Dermatol; 2020 Jun; 47(6):658-662. PubMed ID: 32246533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of Café-au-lait Macules and their Association with the Neurofibromatosis type I Genotype in a Cohort of Greek Children.
    Nasi L; Alexopoulos A; Kokkinou E; Roka K; Tzetis M; Tsipi M; Kakourou T; Kanaka-Gantenbein C; Chrousos G; Kattamis A; Pons R;
    Acta Derm Venereol; 2023 Jun; 103():adv5758. PubMed ID: 37272364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience.
    Kokkinou E; Roka K; Alexopoulos A; Tsina E; Nikas I; Krallis P; Thanopoulou I; Nasi L; Makrygianni E; Tsoutsou E; Kosma K; Tsipi M; Tzetis M; Frysira H; Kattamis A; Pons R
    Postgrad Med; 2019 Sep; 131(7):445-452. PubMed ID: 31443616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic and clinical significance of café-au-lait macules.
    Shah KN
    Pediatr Clin North Am; 2010 Oct; 57(5):1131-53. PubMed ID: 20888463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only.
    Evans DG; Bowers N; Burkitt-Wright E; Miles E; Garg S; Scott-Kitching V; Penman-Splitt M; Dobbie A; Howard E; Ealing J; Vassalo G; Wallace AJ; Newman W; ; Huson SM
    EBioMedicine; 2016 May; 7():212-20. PubMed ID: 27322474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic value of café-au-lait macules.
    Landau M; Krafchik BR
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):877-90; quiz 891-2. PubMed ID: 10365918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jaffe-Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder.
    Stewart DR; Brems H; Gomes AG; Ruppert SL; Callens T; Williams J; Claes K; Bober MB; Hachen R; Kaban LB; Li H; Lin A; McDonald M; Melancon S; Ortenberg J; Radtke HB; Samson I; Saul RA; Shen J; Siqveland E; Toler TL; van Maarle M; Wallace M; Williams M; Legius E; Messiaen L
    Genet Med; 2014 Jun; 16(6):448-59. PubMed ID: 24232412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.